Stereochemistry | RACEMIC |
Molecular Formula | C22H26O4 |
Molecular Weight | 354.4394 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(C)C(=O)C(C(CCCCCC(O)=O)C2=CC=CC=C2)=C(C)C1=O
InChI
InChIKey=ZBVKEHDGYSLCCC-UHFFFAOYSA-N
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
Seratrodast belongs to a class of medication called thromboxane A2/prostaglandin endoperoxide receptor antagonist. Seratrodast blocks the broncho-constrictor effects of certain chemicals (prostaglandins) in the body. Seratrodast also decreases the inflammation by antagonising the thromboxane A2 receptor. Adverse effects include gastrointestinal disturbances, drowsiness, headache, palpitations, and hepatitis. Seradair may interact with Ozagrel.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
It is given in single doses of 80 mg in the evening after food.
Route of Administration:
Oral